Ridgebio provides an AI‑driven enzyme engineering platform that creates native, site‑specific bioconjugation tools for antibodies, peptides and other biologics. Its NativeLink™ enzymes enable homogeneous attachment of multiple payloads without altering the host cell line, disulfide bonds, glycans or primary sequence, while the Pro Trigger linkers and catalytic medicines expand the chemical space for targeted therapies. The integrated wet‑lab and generative‑AI workflow accelerates enzyme discovery, helping pharma and biotech companies develop safer, more effective therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Developing antibody-drug conjugates, peptide therapeutics, and enzyme-based medicines often requires complex chemistry, non‑standard amino acids, or extensive protein engineering, which can limit site‑specific modification, increase manufacturing complexity, and reduce therapeutic efficacy.
Solution
Ridgebio offers an AI‑driven enzyme engineering platform that creates native, site‑specific bioconjugation tools for a range of biologics and small molecules. Their NativeLink™ enzymes enable precise modification of proteins and peptides without altering the host cell line, disulfide bonds, glycans, or primary sequence, allowing homogeneous attachment of multiple payloads. The platform also provides precision linkers (Pro Trigger) and catalytic medicines that expand the chemical space for hard‑to‑reach targets. By integrating wet‑lab data with generative AI, Ridgebio accelerates the design of novel enzymes that improve stability, half‑life, and functionalization of therapeutics, supporting the development of safer and more effective medicines.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing antibody‑drug conjugates, peptide therapeutics, and enzyme‑based drugs, as well as research organizations seeking advanced bioconjugation tools.
Features
- NativeLink™ enzymes that perform site‑specific conjugation on diverse proteins and peptides without genetic re‑engineering
- Capability to generate homogeneous antibody‑drug conjugates, antibody‑oligonucleotide conjugates, radiopharmaceuticals, and other multi‑payload constructs
- Precision linker technology (Pro Trigger) for controlled release and targeted therapy
- AI‑guided enzyme design pipeline that combines experimental data with generative models to accelerate enzyme discovery
- Enzyme platforms for extending peptide/biologic half‑life and enabling novel small‑molecule chemistries inaccessible to traditional synthesis